NCT04434469

A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a first-in-human Phase I, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of RO7297089 and make a preliminary assessment of anti-tumor activity in patients with R/R MM for whom no established therapy for MM is appropriate and available or who are intolerant to those established therapies.

Conditions

• Refractory Multiple Myeloma
• Relapsed Multiple Myeloma

Interventions

Type	Name	Description
DRUG	RO7297089	RO7297089 will be given via intravenous (IV) infusion

Timeline

• Start date: 2020-07-08
• Primary completion: 2022-02-23
• Completion: 2022-02-23
• First posted: 2020-06-16
• Last updated: 2024-07-03
• Results posted: 2024-07-03

Locations

10 sites across 4 countries: Australia, Belgium, Denmark, Norway

Regulatory

• FDA-regulated drug study